ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients

J. Dann, J. Geyston, M. Wassimi, K. Brayman, A. Doyle

University of Virginia Health System, Charlottesville, VA

Meeting: 2020 American Transplant Congress

Abstract number: D-105

Keywords: Dosage, Immunosuppression, Kidney transplantation, Pharmacokinetics

Session Information

Session Name: Poster Session D: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Due to ongoing national drug shortages, our center transitioned to de novo use of LCP-tacrolimus (LCPT) in kidney transplant patients using a conservative dosing strategy. Herein we report the results of a study examining the doses of LCPT required to achieve therapeutic levels with secondary endpoint of time to therapeutic level, incidence of biopsy proven acute rejection (BPAR) and incidence of opportunistic infection in the early post-transplant period.

*Methods: This was a single-center retrospective cohort study of sequential adult kidney transplant alone recipients who received LCPT de novo. Patients were excluded if they were on concomitant CYP3A4/5 inhibitors. All patients received induction with rabbit antithymocyte globulin and maintenance immunosuppression of mycophenolate, prednisone, and tacrolimus with goal trough of 8-10 ng/mL for the first 3 months. LCPT was started using a weight-based strategy with lower doses (0.07-0.1 mg/kg/day) than what has been reported in clinical trials and in package labeling (0.14-0.17 mg/kg/day). Tacrolimus troughs were monitored daily during inpatient admissions and twice weekly during the first 3 months post-transplant.

*Results: Forty patients were included for analysis. Patients were 43% female, with average age of 57 years, mean BMI 30.4 kg/m2 and primarily Caucasian (55%) or African American (38%). Patients had a mean follow up period of 72 days post-transplant. LCPT was started on post-operative day 0 or 1 with mean starting dose of 0.07 mg/kg/day. Patients had a median length of stay of 3.5 days. At time of discharge, 55% of patients had a tacrolimus level <6 ng/mL, 25% had a tacrolimus level 6-11 ng/mL, 20% of patients had a tacrolimus level >11 ng/mL. Following discharge, 62% of patients experienced trough levels >15 ng/mL with a mean maximum trough of 18.6 ng/mL within 30 days of transplant. The mean time to stable, therapeutic levels was 12.7 days achieved on a mean weight-based dose of 0.07 mg/kg/day. The range of doses for therapeutic levels was 0.02-0.19 mg/kg/day. One patient experienced BPAR, 5 patients (12.5%) developed BK viremia, no CMV viremia was seen.

*Conclusions: Use of de novo LCPT with conservative weight-based dosing resulted in the majority of patients experiencing supratherapeutic tacrolimus trough levels with longer than expected time to stable, therapeutic levels. LCPT tacrolimus de novo dosing is dynamic and may require modifications from previously published weight-based dosing strategies based on this experience.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Dann J, Geyston J, Wassimi M, Brayman K, Doyle A. De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/de-novo-dosing-of-lcp-tacrolimus-using-conservative-weight-based-strategy-resulted-in-supratherapeutic-trough-levels-in-majority-of-patients/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences